India Supreme Court Panel Delays Ruling On Novartis Glivec Appeal
This article was originally published in PharmAsia News
India's two-judge panel of the Supreme Court delayed issuing a decision on an appeal by Novartis of the government's denial of a patent for its Glivec (imatinib) blood-cancer drug.
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.